 |
||||
| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
|
||||
| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
*
Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
Clinica Medica, University of Pisa, Italy
Division of Hypertension, Department of Internal Medicine, University of
Michigan Medical Center, Ann Arbor, Michigan
§
Clinical Hypertension Research, Department of Public Health and Social
Sciences, University of Uppsala, Uppsala, Sweden
||
AstraZeneca R&D, Mölndal,
Sweden
¶
Nordic School of Public Health, Göteborg,
Sweden
§§
Centro di Fisiologia Clinica e Ipertensione, University of Milan, Ospedale
Maggiore di Milano and Instituto Auxologico Italiano, Milan, Italy.
Correspondence to Dr. Luis M. Ruilope, Unidad de Hipertension, Hospital 12 de Octubre, 28041 Madrid, Spain. Phone: +34-91-390-82-84; Fax: +34-91-576-56-44; E-mail: Luis_M_Ruilope{at}teleline.es
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionConclusionReferences |
|---|
30% over baseline and final serum creatinine concentration 2 mg/dl)
despite satisfactory reduction of diastolic BP. (3) The results of
this reanalysis of the HOT Study suggest though do not prove that the
association of acetylsalicylic acid with intensive antihypertensive therapy
offers additional benefit in hypertensive patients with reduced renal
function. |
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionConclusionReferences |
|---|
With antihypertensive therapy, the renal prognosis of hypertensive patients has improved dramatically, and evidence recently reviewed (2) indicates that it can be improved further. Tighter BP control is likely to be the main mechanism for this further improvement (3), whereas an additional organ protective role of newer antihypertensive agents, such as angiotensin converting enzyme (ACE) inhibitors, remains a matter of debate (2). However, it is widely known that the cardiovascular system is affected profoundly by the presence of advanced renal failure (4). In essential hypertension, there seems to be a correlation between renal damage and an increased rate of cardiovascular death from the early stages of renal damage. In this context, the Hypertension Detection and Follow-up Program (HDFP) study (5) showed that baseline serum creatinine had a significant prognostic value for 5- and 8-yr all-cause mortality. The presence of proteinuria in hypertensive patients also is a powerful predictor of higher cardiovascular morbidity and mortality (6).
The rationale, background, and principal results of the Hypertension Optimal Treatment (HOT) study have already been published (7,8). In this study, comparison of the incidence of various types of cardiovascular events in the three groups of patients randomized to different diastolic BP targets (with a mean difference in achieved BP of only 2 mmHg among groups) showed a lower incidence of myocardial infarction but not of other cardiovascular events with lower BP targets. However, an observational analysis relating cardiovascular events to achieved BP suggested that the lowest rate of major cardiovascular events occurred at diastolic BP values between 80 and 85 mmHg and at systolic BP values between 130 and 140 mmHg. Furthermore, association of a low dose of acetylsalicylic acid (ASA) with intensive antihypertensive treatment was found to reduce the risk of acute myocardial infarction by 36% without increasing the risk of cerebral bleeding.
This article reports further analyses of the HOT Study data with the aim to assess (1) the value of baseline serum creatinine and its estimated clearance as predictors of cardiovascular events in well-treated hypertensive patients, (2) the effects of intensive lowering of BP on cardiovascular events and renal function in patients with reduced renal function at randomization, and (3) the effects on cardiovascular events of adding ASA to antihypertensive treatment in patients with reduced baseline renal function.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionConclusionReferences |
|---|
90 mmHg, 85 mmHg, 80 mmHg) and to
either ASA (75 mg once daily) or placebo. They were followed for an average
period of 3.8 yr (range, 3.3 to 4.9 yr). Patients were randomized on the basis
of the following baseline variables: age, gender, previous antihypertensive
therapy, smoking, previous myocardial infarction, other coronary heart
disease, stroke, and diabetes mellitus; serum cholesterol and creatinine were
not included in the randomization procedure. Antihypertensive therapy with the
long-acting calcium antagonist felodipine at a dose of 5 mg once a day was
given to all patients. Additional therapy and dose increments in four further
steps were prescribed to reach the randomized target BP. ACE inhibitors or
ß-blockers were added at step 2, and dose titrations were used at step 3
(felodipine 10 mg once a day) or 4 (doubling the dose of either the ACE
inhibitor or the ß-blocker), with the possibility of adding a diuretic or
another antihypertensive drug at step 5. BP was measured with an oscillometric
device (Visomat OZ, D2, International, Hestia, Germany) with the
patient in the seated position at each prerandomization visit, at
randomization, 3 and 6 mo after randomization, and twice a year thereafter.
Major cardiovascular events (acute myocardial infarction, stroke,
cardiovascular death) as well as noncardiovascular deaths were determined by
the Independent Clinical Event Committee (blind to the study group to which
patients were assigned) according to criteria defined in the study
protocol.
Renal Function Measurement
According to the protocol, serum creatinine had to be measured, at each
recruiting center, by standard laboratory techniques in every patient twice,
at baseline and at the final study visit. A baseline serum creatinine value
>3.0 mg/dl was considered as an exclusion criterion. Creatinine clearance
was estimated using the Cockroft and Gault formula
(9). For the final analysis,
the presence of a serum creatinine concentration above 1.5 mg/dl (132.6
µmol/L) was considered as indicative of the presence of chronic renal
failure, and an estimated creatinine clearance 60 ml/min was arbitrarily
taken as indicative of a clinically significant reduction in renal function,
as described previously in the literature
(10,11).
To keep the large trial as simple as possible, the protocol did not require
systematic measurement of proteinuria, and therefore data on proteinuria are
not reported.
Statistical Analyses
Event rates were evaluated separately for patients with serum creatinine
concentrations >1.5 and 1.5 mg/dl and for patients with estimated
creatinine clearance 60 and >60 ml/min at baseline. Risk ratios (with
95% confidence intervals [CI] and P values) were adjusted for the
following baseline variables: achieved systolic and diastolic BP, age, gender,
smoking habits, previous cardiovascular disease, diabetes, and total serum
cholesterol. The adjustments were performed by Poisson regression
(12). A sensitivity analysis
to correct for heterogeneity among different countries was not performed
because both center and nationality were controlled for by the randomization
procedure.
In the analysis of trends for differences between diastolic BP target groups and the effects of ASA compared with placebo, a Cox proportional-hazards model based on a factorial design was used to calculate relative risks. Comparisons between groups were made on a pair-wise basis with one degree of freedom, using t test. For comparisons of proportions, Fisher's exact test was used. Correlation analyses were performed calculating Pearson correlation coefficients.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionConclusionReferences |
|---|
60 ml/min.
As shown in Table 1, at
randomization, the HOT patients with high serum creatinine predominantly were
male and were significantly older. They also more frequently had a history of
myocardial infarction or other sequelae of coronary heart disease, of stroke,
and of diabetes mellitus than those a with serum creatinine value 1.5
mg/dl. The two groups did not differ significantly as far as current smoking
and serum cholesterol concentration were concerned. Patients with low
estimated creatinine clearance (Table
2) were older with a greater prevalence of a history of previous
cardiovascular events and predominantly were women. The predominance of women
in the group with lower estimated creatinine clearance could be explained by
the fact that this parameter is usually lower in women and also because the
Cockroft and Gault formula does not include correction for body surface
area.
|
|
Table 3 compares the rate of
events that occurred in the group of patients with a serum creatinine value
>1.5 mg/dl and 1.5 mg/dl. Risk ratios adjusted for all other baseline
variables except serum creatinine indicate a markedly increased risk for all
types of events considered. The increase in risk ratios for major
cardiovascular events, cardiovascular, and total mortality was statistically
highly significant. When considering patients with less markedly reduced renal
function (estimated creatinine clearance 60 ml/min versus
patients with values >60 ml/min) adjusted risk ratios for all types of
events were less markedly elevated but still statistically significant with
the exception of the risk ratio for myocardial infarction
(Table 4).
|
|
Effects of Intensive BP Lowering in Patients with Reduced Renal
Function
Control of BP. During follow-up, the achieved values of systolic and
diastolic BP were not different between patients with a baseline serum
creatinine value >1.5 mg/dl and 1.5 mg/dl
(Table 5). The percentages of
patients who achieved the diastolic BP target to which they had been
randomized did not differ significantly between patients with higher or lower
baseline serum creatinine concentrations. More intensive therapy was, however,
necessary for patients with than those without reduced renal function
(Table 6).
|
|
Cardiovascular Events According to Randomized Diastolic BP Target.
The incidence of major cardiovascular events in patients with a serum
creatinine value >1.5 mg/dl was very similar in the three groups randomized
to different diastolic BP targets (26.5, 26.7, and 27.9 per 1000 patient
years). There were on the whole too few events to analyze interactions between
BP target and type of event. There were more events in the larger group of
patients with an estimated creatinine clearance 60 ml/min (but the
absolute rate was lower than in patients with a serum creatinine concentration
>1.5 mg/dl). Cardiovascular events tended to be less frequent in patients
with the lower diastolic BP target, but this was not statistically significant
(Figure 1).
|
Effects on Renal Function. Baseline and final serum creatinine
concentrations were available for 15,601 patients (83.0% of the entire study
population). Of these, 15,237 patients had baseline serum creatinine 1.5
mg/dl and 364 had baseline values >1.5 mg/dl. Of the 3048 patients whose
final serum creatinine was not available, 491 (1.6%) had been lost to the
study follow-up, 589 (1.9%) had died, and 1968 (6.5%) specifically failed to
have final serum creatinine measurement. Although the rate of death was
significantly higher among patients with higher serum creatinine, as shown in
Table 3, loss to follow-up and
failure to remeasure serum creatinine at the final visit were similar among
patients with higher and lower values at baseline (10.8 and 11.1%,
respectively).
Baseline serum creatinine concentrations, mean 1.00 mg/dl (SD 0.25), were
unrelated to baseline diastolic BP both in men (r = 0.01) and in
women (r = -0.004), as well as in patients older than 65 yr
(r = -0.003) or younger than 65 yr (r = 0.03). No
significant changes were seen in serum creatinine values at the end of the
3.8-yr treatment period, in all HOT Study participants considered as a single
group or in the three diastolic BP target subgroups
(Table 7). Table 7 also shows that no
significant changes in serum creatinine had occurred at the end of the study
in any of the diastolic BP target subgroups. This was true in patients with
higher or lower baseline serum creatinine concentrations as well as in
patients with higher or lower estimated creatinine clearance. Baseline and
final serum creatinine concentrations were not influenced by diabetes
mellitus, ischemic heart disease, or age. Despite that mean initial and final
serum creatinine values were not different, an increase in the final value of
serum creatinine concentration by 30% or more of the baseline values was seen
in 1220 patients (7.8%), corresponding to 1185 (7.6%) patients with initial
serum creatinine 1.5 mg/dl and 35 patients (0.22%) with higher initial
values. A decrease in serum creatinine by a similar amount was observed in 652
patients (4.18% of the total sample). Ninety patients with a serum creatinine
increase 30% reached final values of 2.0 mg/dl. This amounted to only
0.58% of the total study population. Among patients with initial serum
creatinine >1.5 mg/dl, 30 additional patients reached a final creatinine
2.0 mg/dl, despite an increment <30%, or already had a baseline
creatinine 2.0 mg/dl, so that on the whole 120 (0.8%) of 15,601 patients
in the HOT Study had serum creatinine 2.0 mg/dl at the final visit (17.9%
of patients with baseline creatinine >1.5 mg/dl and 0.4% of patients with
baseline creatinine 1.5 mg/dl).
|
Effects of ASA
Table 8 provides the data on
the effect of ASA according to baseline serum creatinine concentration.
Patients with baseline serum creatinine values >1.5 mg/dl and receiving ASA
tended to have lower rates of all types of events. Presumably because of the
relatively small number of patients in this group, the ASA effects did not
reach the conventional level of statistical significance.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionConclusionReferences |
|---|
An increase of serum creatinine in patients with essential hypertension is commonly attributed to the presence of nephrosclerosis. This condition is characterized by hyalinization of arterioles and by fibroplastic intimal thickening of small arteries. It has been reported that hyalinization of renal arterioles is more marked in patients with coronary heart disease than in matched control subjects (14). Furthermore, autopsy studies (15) of otherwise asymptomatic young people also showed that hyalinization in the renal arterioles was a marker of advanced coronary atherosclerosis.
The Hypertension Detection and Follow-up Program trial (5) documented that the baseline serum creatinine concentrations have a significant prognostic value for 8-yr mortality. For people with a serum creatinine concentration >1.7 mg/dl, mortality (after adjustment for other cardiovascular risk factors) was 2.22 times higher than that of all other participants. In agreement with these data, we found a risk ratio of 2.86 in patients with serum creatinine >1.5 mg/dl.
The recent data of the Framingham Study (11) document that mild renal insufficiency, defined as serum creatinine >1.5 mg/dl, is common (8.7% in men and 8.0% in women) and is associated with a high prevalence of cardiovascular disease. In the HOT Study, assignment to different diastolic BP targets did not significantly influence the rate of cardiovascular events, but the differences in achieved BP among groups were small. Furthermore, serum creatinine concentrations had not been considered in the randomization procedure.
Effects on BP
As described previously
(16), target diastolic BP
could be reached even in patients with diminished renal function at baseline.
Good control of BP necessitated more intensive antihypertensive treatment,
however. Following the new guidelines for the management of hypertension
(17,
18), the control of diastolic
BP obtained in the HOT Study was adequate both for patients initially
presenting with normal renal function and for those with impaired renal
function. The mean diastolic BP achieved throughout the trial was 82 mmHg, in
line with the recommendation to achieve values lower than 85 mmHg. However,
the control of systolic BP remained more than 10 mmHg (mean) above the goal of
<130 mmHg, which has been recommended for patients with elevated levels of
serum creatinine. Control of systolic BP was not the aim of this study, and
when it was designed the new goals had not been established. Whether
incomplete control of systolic BP was responsible for the high incidence of
all events in patients with diminished renal function cannot be decided on the
basis of available data.
Effects on Renal Function
The assessment of the effects of intensive lowering of BP on renal function
was partly limited by the fact that serum creatinine was measured only at
baseline and at the final visit. Consequently, we do not have the information
on the 3.3% of patients who died during the study. Furthermore, approximately
10% of the patients failed to have the final serum creatinine measurement.
Despite these reservations, it can be concluded that the overall good BP
control achieved in this study did not have an adverse effect on serum
creatinine values, at least in the great majority of the patients. These
results are in agreement with those published by Mandhavan et al.
(3, who treated and followed
2125 men with mild and moderate hypertension over an average of 5 yr with good
control of BP. Conversely, in the HDFP study, serum creatinine increased by
0.14 to 0.2 mg/dl at the end of 5 yr, whereas in the HOT study, patients we
observed had an increase of only 0.01 mg/dl over 3.8 yr.
In the HOT Study, not only was renal function well preserved, but also the
rate of cardiovascular events and death was low. In fact, the event rate in
this study was much lower than the average rate calculated in the
meta-analysis of all previous antihypertensive treatment trials
(19). There is a small group
of patients in whom renal function deteriorates progressively despite an
adequate BP control, which is in agreement with what has been reported in the
literature
(20,21).
To take account of regression toward the mean, we adopted a conservative
definition of deterioration of renal function, i.e., an increase in
serum creatinine exceeding 30% with a final creatinine concentration of
2.0 mg/dl. Whereas the proportion of patients who showed a creatinine
increase >30% was 7.8%, only 90 patients fulfilled both criteria of renal
deterioration, yielding an overall rate of approximately 0.5%. On the whole,
at the end of the study, 120 patients had serum creatinine levels 2.0
mg/dl. Because of the small size of this group, it is inappropriate to analyze
their baseline characteristics in detail, but patients whose renal function
deteriorated had mostly baseline serum creatinine >1.5 mg/dl and were
equally distributed among the three groups randomized to different BP
targets
Effects of ASA
The benefit of adding a low dose of ASA to antihypertensive therapy was
difficult to prove in patients with elevated values of serum creatinine,
because the numbers were small. Nevertheless, the risk ratios favoring aspirin
versus placebo were low and approached, though did not reach,
statistical significance.
|
Conclusion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionConclusionReferences |
|---|
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionConclusionReferences |
|---|
This article has been cited by other articles:
 |
|
 |
|
  F. Pizzarelli, F. Lauretani, S. Bandinelli, G. B. Windham, A. M. Corsi, S. V. Giannelli, L. Ferrucci, and J. M. Guralnik Predictivity of survival according to different equations for estimating renal function in community-dwelling elderly subjects Nephrol. Dial. Transplant., November 6, 2008; (2008) gfn594v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. P. Liew, J. R. Bartholomew, S. Demirjian, J. Michaels, and M. J. Schreiber Jr. Combined Effect of Chronic Kidney Disease and Peripheral Arterial Disease on All-Cause Mortality in a High-Risk Population Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 1084 - 1089. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. C. Astor, S. I. Hallan, E. R. Miller III, E. Yeung, and J. Coresh Glomerular Filtration Rate, Albuminuria, and Risk of Cardiovascular and All-Cause Mortality in the US Population Am. J. Epidemiol., May 15, 2008; 167(10): 1226 - 1234. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Rosamond, K. Flegal, K. Furie, A. Go, K. Greenlund, N. Haase, S. M. Hailpern, M. Ho, V. Howard, B. Kissela, et al. Heart Disease and Stroke Statistics--2008 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation, January 29, 2008; 117(4): e25 - e146. [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Seliger and W.T. Longstreth Jr Lessons About Brain Vascular Disease From Another Pulsating Organ, the Kidney Stroke, January 1, 2008; 39(1): 5 - 6. [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Schneider, E. Ferrannini, R. DeFronzo, G. Schernthaner, J. Yates, and E. Erdmann Effect of Pioglitazone on Cardiovascular Outcome in Diabetes and Chronic Kidney Disease J. Am. Soc. Nephrol., January 1, 2008; 19(1): 182 - 187. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Daly Is early chronic kidney disease an important risk factor for cardiovascular disease?: A Background Paper prepared for the UK Consensus Conference on Early Chronic Kidney Disease Nephrol. Dial. Transplant., September 1, 2007; 22(suppl_9): ix19 - ix25. [Full Text] [PDF]
|
|
|
|
|
|
W. W. M. Saweirs and J. Goddard What are the best treatments for early chronic kidney disease?: A Background Paper prepared for the UK Consensus Conference on Early Chronic Kidney Disease Nephrol. Dial. Transplant., September 1, 2007; 22(suppl_9): ix31 - ix38. [Full Text] [PDF]
|
|
|
|
|
|
E. L. Schiffrin, M. L. Lipman, and J. F.E. Mann Chronic Kidney Disease: Effects on the Cardiovascular System Circulation, July 3, 2007; 116(1): 85 - 97. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Maaravi, M. Bursztyn, R. Hammerman-Rozenberg, and J. Stessman Glomerular filtration rate estimation and mortality in an elderly population QJM, July 1, 2007; 100(7): 441 - 449. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Authors/Task Force Members:, G. Mancia, G. De Backer, A. Dominiczak, R. Cifkova, R. Fagard, G. Germano, G. Grassi, A. M. Heagerty, S. E. Kjeldsen, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur. Heart J., June 11, 2007; (2007) ehm236v1. [Full Text] [PDF]
|
|
|
|
|
|
A. Schulz, J. Weiss, M. Schlesener, J. Hansch, M. Wehland, N. Wendt, P. Kossmehl, A. Sietmann, D. Grimm, M. Stoll, et al. Development of Overt Proteinuria in the Munich Wistar Fromter Rat Is Suppressed by Replacement of Chromosome 6 in a Consomic Rat Strain J. Am. Soc. Nephrol., January 1, 2007; 18(1): 113 - 121. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Sarafidis and G. L. Bakris Microalbuminuria and chronic kidney disease as risk factors for cardiovascular disease Nephrol. Dial. Transplant., September 1, 2006; 21(9): 2366 - 2374. [Full Text] [PDF]
|
|
|
|
|
|
M. Tonelli, N. Wiebe, B. Culleton, A. House, C. Rabbat, M. Fok, F. McAlister, and A. X. Garg Chronic Kidney Disease and Mortality Risk: A Systematic Review J. Am. Soc. Nephrol., July 1, 2006; 17(7): 2034 - 2047. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Tonelli, P. Jose, G. Curhan, F. Sacks, E. Braunwald, M. Pfeffer, and Cholesterol and Recurrent Events (CARE) Trial Inve Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial BMJ, June 17, 2006; 332(7555): 1426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Meisinger, A. Doring, H. Lowel, and for the KORA Study Group Chronic kidney disease and risk of incident myocardial infarction and all-cause and cardiovascular disease mortality in middle-aged men and women from the general population Eur. Heart J., May 2, 2006; 27(10): 1245 - 1250. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Zoccali, R. Maio, G. Tripepi, F. Mallamaci, and F. Perticone Inflammation as a Mediator of the Link between Mild to Moderate Renal Insufficiency and Endothelial Dysfunction in Essential Hypertension. J. Am. Soc. Nephrol., April 1, 2006; 17(4_suppl_2): S64 - S68. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A Garcia-Donaire and L. M Ruilope Spotlight on Renin: Cardiovascular outcomes in chronic kidney disease and suppression of the renin-angiotensin system Journal of Renin-Angiotensin-Aldosterone System, March 1, 2006; 7(1): 56 - 58. [PDF]
|
|
|
|
|
|
Y. Maaravi, M. Bursztyn, R. Hammerman-Rozenberg, A. Cohen, and J. Stessman Moderate renal insufficiency at 70 years predicts mortality QJM, February 1, 2006; 99(2): 97 - 102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Gil, S. Justo, and C. Caramelo Cardio-renal failure: an emerging clinical entity Nephrol. Dial. Transplant., September 1, 2005; 20(9): 1780 - 1783. [Full Text] [PDF]
|
|
|
|
|
|
R. Vanholder, Z. Massy, A. Argiles, G. Spasovski, F. Verbeke, N. Lameire, and for the European Uremic Toxin Work Group (EUTox) Chronic kidney disease as cause of cardiovascular morbidity and mortality Nephrol. Dial. Transplant., June 1, 2005; 20(6): 1048 - 1056. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Sarnak, R. Katz, C. O. Stehman-Breen, L. F. Fried, N. S. Jenny, B. M. Psaty, A. B. Newman, D. Siscovick, M. G. Shlipak, and and the Cardiovascular Health Study* Cystatin C Concentration as a Risk Factor for Heart Failure in Older Adults Ann Intern Med, April 5, 2005; 142(7): 497 - 505. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. P. Kopyt Slowing Progression Along the Renal Disease Continuum J Am Osteopath Assoc, April 1, 2005; 105(4): 207 - 215. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kalantar-Zadeh, K. C Abbott, A. K Salahudeen, R. D Kilpatrick, and T. B Horwich Survival advantages of obesity in dialysis patients Am. J. Clinical Nutrition, March 1, 2005; 81(3): 543 - 554. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. W. de Leeuw, L. M. Ruilope, C. R. Palmer, M. J. Brown, A. Castaigne, G. Mancia, T. Rosenthal, and G. Wagener Clinical Significance of Renal Function in Hypertensive Patients at High Risk: Results From the INSIGHT Trial Arch Intern Med, December 13, 2004; 164(22): 2459 - 2464. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Go, G. M. Chertow, D. Fan, C. E. McCulloch, and C.-y. Hsu Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization N. Engl. J. Med., September 23, 2004; 351(13): 1296 - 1305. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Perticone, R. Maio, G. Tripepi, and C. Zoccali Endothelial Dysfunction and Mild Renal Insufficiency in Essential Hypertension Circulation, August 17, 2004; 110(7): 821 - 825. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Andrews Review: Renal dysfunction as a marker of increased vascular risk The British Journal of Diabetes & Vascular Disease, May 1, 2004; 4(3): 152 - 155. [Abstract] [PDF]
|
|
|
|
|
|
F. A. McAlister, J. Ezekowitz, M. Tonelli, and P. W. Armstrong Renal Insufficiency and Heart Failure: Prognostic and Therapeutic Implications From a Prospective Cohort Study Circulation, March 2, 2004; 109(8): 1004 - 1009. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Ruilope New European guidelines for management of hypertension: what is relevant for the nephrologist Nephrol. Dial. Transplant., March 1, 2004; 19(3): 524 - 528. [Full Text] [PDF]
|
|
|
|
|
|
E. Ritz and W. M. McClellan Overview: Increased Cardiovascular Risk in Patients with Minor Renal Dysfunction: An Emerging Issue with Far-Reaching Consequences J. Am. Soc. Nephrol., March 1, 2004; 15(3): 513 - 516. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Pinkau, K. F. Hilgers, R. Veelken, and J. F. E. Mann How Does Minor Renal Dysfunction Influence Cardiovascular Risk and the Management of Cardiovascular Disease? J. Am. Soc. Nephrol., March 1, 2004; 15(3): 517 - 523. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Fox, M. G. Larson, E. P. Leip, B. Culleton, P. W. F. Wilson, and D. Levy Predictors of New-Onset Kidney Disease in a Community-Based Population JAMA, |
